A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer

NCT05047250 PHASE3 ACTIVE_NOT_RECRUITING

This is a Phase III, single arm, multicenter study designed to evaluate the efficacy and safety of atezolizumab in high PD-L1 expression, chemotherapy-naïve, without a sensitizing EGFR mutation or ALK translocation patients with stage IV non-squamous or squamous NSCLC.

Details

Lead sponsor	Hoffmann-La Roche
Phase	PHASE3
Status	ACTIVE_NOT_RECRUITING
Enrolment	60
Start date	Tue Jun 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Aug 30 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Non-Small Cell Lung Cancer

Interventions

• Atezolizumab

Countries

China